Conavi Medical Inc.
YU1.SG
0.05 EUR
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer YU1.SG
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Conavi Medical Corp. focuses on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. It offers Novasight Hybrid System, a system that combines intravascular ultrasound and optical coherence tomography to enable simultaneous and co-registered imaging of coronary arteries. The company is based in Toronto, Canada.
Aktuelle News
-
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
Vorschau anzeigen
Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone PaymentAchieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imagin
-
Conavi Medical Corp. Announces Closing of $10M Public Offering
Vorschau anzeigen
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has closed its previously announced equity offering for aggregate gross proceeds of $10 million (
-
Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants
Vorschau anzeigen
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, July 29, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering.
-
Conavi Medical Announces JSCAI Publication Demonstrating the Clinical Utility of Hybrid IVUS OCT Imaging
Vorschau anzeigen
Publication demonstrates how complementary IVUS and OCT information supports lesion assessment, treatment planning, and stent optimization while helping manage contrast useTORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a c
-
Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund
Vorschau anzeigen
Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid IVUS-OCT imaging systemTORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (“Conavi” or the “Company”) (TSXV: CNVI; OTCQB: CNVIF), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedure